טוען...
Randomised phase II trial of irinotecan plus cisplatin vs irinotecan, cisplatin plus etoposide repeated every 3 weeks in patients with extensive-disease small-cell lung cancer
Patients with previously untreated extensive-disease small-cell lung cancer were treated with irinotecan 60 mg m(−2) on days 1 and 8 and cisplatin 60 mg m(−2) on day 1 with (n=55) or without (n=54) etoposide 50 mg m(−2) on days 1–3 with granulocyte colony-stimulating factor support repeated every 3...
שמור ב:
| Main Authors: | , , , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Nature Publishing Group
2008
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2259188/ https://ncbi.nlm.nih.gov/pubmed/18253118 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6604233 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|